Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer
Jesenia M. Perez, Justin Hwang, Britt K. Erickson, Stefani N. Thomas. Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer. // Clinical and Translational Medicine. – 2026. – DOI: 10.1002/ctm2.70890. – URL: https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70890?af=R
Jesenia M. Perez, Justin Hwang, Britt K. Erickson, & Stefani N. Thomas (2026). Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70890
Jesenia M. Perez, et al. “Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer.” Clinical and Translational Medicine, 2026. doi:10.1002/ctm2.70890.
@article{Perez2026,
title = {Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer},
author = {Perez, Jesenia M. and Hwang, Justin and Erickson, Britt K. and Thomas, Stefani N.},
journal = {Clinical and Translational Medicine},
year = {2026},
doi = {10.1002/ctm2.70890},
url = {https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70890?af=R}
}